Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market, Size, Share, Trends, Epidemiology Forecast till 2030

Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market, Size, Share, Trends, Epidemiology Forecast till 2030

“DelveInsight”
DelveInsight’s ‘Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast – 2030’ report delivers an in-depth understanding of the PD-L1 NSCLC ,historical and forecasted epidemiology as well as the PD-L1 NSCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

PD-L1 NSCLC market report provides current treatment practices, emerging drugs, PD-L1 NSCLC market share of the individual therapies, current and forecasted PD-L1 NSCLC market size from 2017 to 2030 segmented by seven major markets. The Report also covers current PD-L1 NSCLC treatment practices/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

 

Key Highlights from PD-L1 NSCLC market report:-

  • Programmed death-ligand 1 (PD-L1) mutated NSCLC total cases in 7MM in 2017 was 242,014
  • Programmed death-ligand 1 (PD-L1) NSCLC cases in the United States was 89,597 in 2017. 
  • Programmed death-ligand 1 (PD-L1) NSCLC cases in Spain in 2017 was 11,585. 
  • The total cases of Programmed death-ligand 1 (PD-L1) mutated NSCLC in EU5 countries in 2017 were
    • Germany – 28,509 cases
    • France – 20,110 cases
    • Italy – 17,021 cases 
    • Spain – 11,585 cases 
    • The United Kingdom –22,192 cases

 

Request for sample pages

 

Scope of the Report

• The report covers the descriptive overview of PD-L1 NSCLC, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.

• Comprehensive insight has been provided into thePD-L1 NSCLC epidemiology and treatment in the 7MM.

• Additionally, an all-inclusive account of both the current and emerging therapies for PD-L1 NSCLC is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

• A detailed review of PD-L1 NSCLC market; historical and forecasted is included in the report, covering drug outreach in the 7MM.

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global PD-L1 NSCLC market.

 

Request for sample pages

 

Programmed death-ligand 1 (PD-L1) mutated NSCLC market size in 7MM was USD 6,536 million in 2017. 

 

PD-L1 NSCLC Market Drivers

  • Increasing Use of Biomarker Testing
  • Increase in the Mutation Specific Trials Activity
  • Increasing Incidence of Programmed death-ligand 1 (PD-L1)  mutated NSCLC

 

PD-L1 NSCLC Market Barriers

  • Cost-Effectiveness of Therapies
  • Cost of Therapies
  • Burden of Disease

 

PD-L1 NSCLC Treatment

PD-1/PD-L1 blocking antibodies therapy is recommended for the patients showing PD-L1 expressions. In recent years, immunotherapy has revolutionized and changed the standard of care in patients with NSCLC. Immune checkpoint inhibitors, fundamentally those that act by blocking PD-1 and its ligand, the PD-L1, have emerged as novel treatment strategies in NSCLC, demonstrating undoubted superiority over chemotherapy in terms of efficacy.

Several of these immune checkpoint modulators have recently gained regulatory approval for the treatment of advanced NSCLC, such as Opdivo (nivolumab), Tecentriq (atezolizumab), Keytruda (pembrolizumab, and recently, Imfinzi (durvalumab). Among all of the approved PD-1/PD-L1 inhibitors, the NSCLC therapy area is dominated by Keytruda (pembrolizumab), with revenues from this particular market helping the drug to achieve a hit status.

Table of contents

1. Key Insights

2. Executive Summary of PD-L1 NSCLC

3. SWOT Analysis of PD-L1 NSCLC

4. PD-L1 NSCLC Market Overview at a Glance

4.1. Total Market Share (%) Distribution of PD-L1 NSCLC in 2017: By Country

4.2. Total Market Share (%) Distribution of PD-L1 NSCLC in 2030: By Country

5. PD-L1 Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview

5.1. Introduction

5.1.1. Cellular Classification of NSCLC

5.1.2. Signs and Symptoms of NSCLC

5.1.3. Risk Factors of Lung Cancer

5.1.4. Causes of NSCLC

5.1.5. Disease Biology: NSCLC

6. Diagnosis of PD-L1 NSCLC

6.1. Diagnostic Algorithm for NSCLC

6.2. Stages of NSCLC

6.3. Staging System

7. Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Total Incident cases of NSCLC patients in the 7MM

7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM

7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM

7.4. The United States Epidemiology

7.4.1. Total Incident cases of NSCLC patients in the United States

7.4.2. Total Incident cases of NSCLC patients by Histology in the United States

7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States

7.4.4. Total PD-L1 NSCLC cases in the United States

7.4.5. Total PD-L1 NSCLC Treated patient Pool in the United States

8. EU-5 Epidemiology

8.1. Germany

8.1.1. Total Incident cases of NSCLC patients in Germany

8.1.2. Total Incident cases of NSCLC patients by Histology in Germany

8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany

8.1.4. Total PD-L1 NSCLC cases in Germany

8.1.5. Total PD-L1 NSCLC Treated patient Pool in Germany

8.2. France

8.2.1. Total Incident cases of NSCLC patients in France

8.2.2. Total Incident cases of NSCLC patients by Histology in France

8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France

8.2.4. Total PD-L1 NSCLC cases in France

8.2.5. Total PD-L1 NSCLC Treated patient Pool in France

8.3. Italy

8.3.1. Total Incident cases of NSCLC patients in Italy

8.3.2. Total Incident cases of NSCLC patients by Histology in Italy

8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy

8.3.4. Total PD-L1 NSCLC cases in Italy

8.3.5. Total PD-L1 NSCLC Treated patient Pool in Italy

8.4. Spain

8.4.1. Total Incident cases of NSCLC patients in Spain

8.4.2. Total Incident cases of NSCLC patients by Histology in Spain

8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain

8.4.4. Total PD-L1 NSCLC cases in Spain

8.4.5. Total PD-L1 NSCLC Treated patient Pool in Spain

8.5. The United Kingdom

8.5.1. Total Incident cases of NSCLC patients in the United Kingdom

8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom

8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom

8.5.4. Total PD-L1 NSCLC cases in the United Kingdom

8.5.5. Total PD-L1 NSCLC Treated patient Pool in the United Kingdom

9. Japan Epidemiology

9.1. Japan

9.1.1. Total Incident cases of NSCLC patients in Japan

9.1.2. Total Incident cases of NSCLC patients by Histology in Japan

9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan

9.1.4. Total PD-L1 NSCLC cases in Japan

9.1.5. Total PD-L1 NSCLC Treated patient Pool in Japan

10. Current Treatment Practices: PD-L1 NSCLC

10.1. Advanced/Metastatic NSCLC Treatment Algorithm

10.2. Chemotherapy

10.3. Targeted Therapy

10.4. Immunotherapy

10.5. Surgery

10.6. Radiation Therapy

10.7. Stage-wise Treatment Options of NSCLC

11. Guideline of NSCLC

11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020

11.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018

11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018

12. Unmet Needs of PD-L1 NSCLC

13. Key Endpoints in NSCLC Clinical Trials

14. PD-L1 NSCLC Marketed Therapies

14.1. Key Cross

14.2. Imfinzi (Durvalumab): AstraZeneca

14.2.1. Product Description

14.2.2. Regulatory Milestones

14.2.3. Other Developmental Activities

14.2.4. Pivotal Clinical Trials

14.2.5. Ongoing Current Pipeline Activity

14.2.6. Safety and Efficacy of Ongoing Clinical Trials

14.3. Opdivo (Nivolumab): Bristol-Myers Squibb

14.3.1. Product Description

14.3.2. Regulatory Milestones

14.3.3. Other Developmental Activities

14.3.4. Pivotal Clinical Trials

14.3.5. Ongoing Current Pipeline Activity

14.4. Tecentriq (Atezolizumab): Genentech/Hoffmann-La Roche

14.4.1. Product Description

14.4.2. Regulatory Milestones

14.4.3. Other Developmental Activities

14.4.4. Pivotal Clinical Trials

14.4.5. Ongoing Current Pipeline Activity

14.5. Keytruda (Pembrolizumab): Merck

14.5.1. Product Description

14.5.2. Regulatory Milestones

14.5.3. Other Developmental Activities

14.5.4. Pivotal Clinical Trials

14.5.5. Ongoing Current Pipeline Activity

15. Emerging Therapies

15.1. Canakinumab (ACZ885): Novartis Pharmaceuticals

15.1.1. Product Description

15.1.2. Clinical Development

15.2. Avelumab (Bavencio): Merck KGaA and Pfizer

15.2.1. Product Description

15.2.2. Clinical Development

15.2.3. Safety and Efficacy

15.3. Libtayo (Cemiplimab): Regeneron Pharmaceuticals

15.3.1. Product Description

15.3.2. Clinical Development

15.3.3. Safety and Efficacy

15.4. M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA

15.4.1. Product Description

15.4.2. Clinical Development

15.4.3. Safety and Efficacy

16. PD-L1Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis

16.1. Key Findings

16.2. Market Outlook: 7MM

17. PD-L1—Market Size

17.1. Total Market Size of PD-L1 NSCLC in the 7MM

17.2. Market Size of PD-L1 NSCLC by Therapeutic Class in the 7MM

17.3. United States Market Size

17.3.1. Total Market size of PD-L1 NSCLC in the United States

17.4. EU-5 Market Size

17.4.1. Germany Market Size

17.4.2. France Market Size

17.4.3. Italy Market Size

17.4.4. Spain Market Size

17.4.5. United Kingdom Market Size

17.5. Japan Market Size

17.5.1. Total Market size of PD-L1 NSCLC in Japan

18. Market Access and Reimbursement of PD-L1 NSCLC Therapies

19. PD-L1 NSCLC Market Drivers 

20. PD-L1 NSCLC Market Barriers 

21. Appendix

21.1. Bibliography

21.2. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: DelveInsight
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/